Literature DB >> 18340447

Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Anthony P Adamis1, Adrienne J Berman.   

Abstract

There is an accumulating body of evidence that immunological mechanisms play a prominent role in the pathogenesis of diabetic retinopathy (DR), which is characterized by many features typical of inflammation. The upregulation of cytokines and other inflammatory mediators leading to persistent low-grade inflammation and an influx of leukocytes, is believed to contribute actively to DR-associated damage to the retinal vasculature and retinal neovascularization. This review will describe preclinical and clinical studies that document an inflammatory basis for DR and that support the use of nonsteroidal anti-inflammatory drugs, corticosteroids, and anti-vascular endothelial growth factor agents in its treatment. In addition, emerging therapeutic approaches based on ongoing investigations will be discussed, including those involving blockade of angiotensin receptors and other molecular targets such as tumor necrosis factor-alpha.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18340447     DOI: 10.1007/s00281-008-0111-x

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  138 in total

1.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

2.  Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.

Authors:  Timothy S Kern; Casey M Miller; Yunpeng Du; Ling Zheng; Susanne Mohr; Sherry L Ball; M Kim; Jeffrey A Jamison; David P Bingaman
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

3.  Angiopoietin concentrations in diabetic retinopathy.

Authors:  J I Patel; P G Hykin; Z J Gregor; M Boulton; I A Cree
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

Review 4.  Intravitreal triamcinolone acetonide: a change in a paradigm.

Authors:  Jost B Jonas
Journal:  Ophthalmic Res       Date:  2006-06-06       Impact factor: 2.892

5.  Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus.

Authors:  N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller
Journal:  Lancet       Date:  1998-01-03       Impact factor: 79.321

6.  Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy.

Authors:  Verena B Gerl; Jürgen Bohl; Susanne Pitz; Bernhard Stoffelns; Norbert Pfeiffer; Sucharit Bhakdi
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-04       Impact factor: 4.799

7.  Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin.

Authors:  A J Barber; E Lieth; S A Khin; D A Antonetti; A G Buchanan; T W Gardner
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

8.  VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Authors:  Tomohiko Usui; Susumu Ishida; Kenji Yamashiro; Yuichi Kaji; Vasiliki Poulaki; Johnny Moore; Tara Moore; Shiro Amano; Yoshitaka Horikawa; Darlene Dartt; Matthew Golding; David T Shima; Anthony P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

10.  Hypoxic regulation of vascular endothelial growth factor in retinal cells.

Authors:  L P Aiello; J M Northrup; B A Keyt; H Takagi; M A Iwamoto
Journal:  Arch Ophthalmol       Date:  1995-12
View more
  136 in total

Review 1.  Inflammation in diabetic retinopathy.

Authors:  Johnny Tang; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2011-05-25       Impact factor: 21.198

Review 2.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

3.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

4.  A(₂A) adenosine receptor (A(₂A)AR) as a therapeutic target in diabetic retinopathy.

Authors:  Ahmed S Ibrahim; Mamdouh M El-Shishtawy; Wenbo Zhang; Ruth B Caldwell; Gregory I Liou
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 5.  Retinal pigment epithelium differentiation of stem cells: current status and challenges.

Authors:  Basak E Uygun; Nripen Sharma; Martin Yarmush
Journal:  Crit Rev Biomed Eng       Date:  2009

Review 6.  The pathogenesis of early retinal changes of diabetic retinopathy.

Authors:  G B Arden; S Sivaprasad
Journal:  Doc Ophthalmol       Date:  2012-02       Impact factor: 2.379

7.  Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.

Authors:  D M Paskowitz; Q D Nguyen; P Gehlbach; J T Handa; S Solomon; W Stark; O Shaikh; C Semba; T R Gadek; D V Do
Journal:  Eye (Lond)       Date:  2012-04-27       Impact factor: 3.775

8.  Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study.

Authors:  Catherine A Cukras; Philip Petrou; Emily Y Chew; Catherine B Meyerle; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-06-22       Impact factor: 4.799

9.  Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.

Authors:  Neil M Bressler; Allison R Edwards; Roy W Beck; Christina J Flaxel; Adam R Glassman; Michael S Ip; Craig Kollman; Baruch D Kuppermann; Thomas W Stone
Journal:  Arch Ophthalmol       Date:  2009-12

10.  Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Authors:  Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.